Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;52(1):35-39.
doi: 10.1016/j.idnow.2021.10.002. Epub 2021 Oct 8.

Evolution of baseline characteristics and severe outcomes in COVID-19 inpatients during the first and second waves in Northeastern France

M Martinot  1 , M Eyriey  2 , S Gravier  3 , D Kayser  3 , C Ion  3 , M Mohseni-Zadeh  3 , J C Ongagna  2 , A Schieber  2 , C Kempf  2 ; Centre Alsace Study Group
Affiliations

Evolution of baseline characteristics and severe outcomes in COVID-19 inpatients during the first and second waves in Northeastern France

M Martinot et al. Infect Dis Now. 2022 Feb.

Abstract

Objectives: Two COVID-19 epidemic waves occurred in France in 2020. This single-center retrospective study compared patients' characteristics and outcomes.

Patients and methods: We included all patients with confirmed COVID-19 admitted to Colmar Hospital in March (n=600) and October/November (n=205) 2020.

Results: Median ages, sex ratio, body mass index, and number of comorbidities were similar in wave 1 and 2 patients. Significant differences were found for temperature (38°C vs. 37.2), need for oxygen (38.6% vs. 26.8%), high-flow cannula (0% vs. 8.3%), and steroid use (6.3% vs. 54.1%). Intensive care unit (ICU) hospitalizations (25.5% vs. 15.1%, OR: 0.44, 95% CI [0.28; 0.68], P=0.002) and deaths (19.2% vs. 12.7%, OR: 0.61, 95% CI [0.37; 0.98], P=0.04) decreased during the second wave. Except for cardiovascular events (5.5% vs. 10.2%), no change was observed in extrapulmonary events.

Conclusions: Deaths and ICU hospitalizations were significantly reduced during the second epidemic wave.

Keywords: COVID waves; COVID-19; Extrapulmonary complications; Outcome; SARS-CoV-2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Death rate curves. Kaplan–Meier product limit estimates with two-sided 95% confidence interval (wave 1 blue, wave 2 green). Day 0 is the day of hospitalization. Patients alive at the date of last available information were censored (+) at that date.
See this image and copyright information in PMC

References

    1. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. Gupta A., Madhavan M.V., Sehgal K., Nair N., Mahajan S., Sehrawat T.S., et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–1032. doi: 10.1038/s41591-020-0968-3. - DOI - PMC - PubMed
    1. Martinot M., Eyriey M., Gravier S., Bonijoly T., Kayser D., Ion C., et al. Predictors of mortality, ICU hospitalization, and extrapulmonary complications in COVID-19 patients. Infect Dis Now. 2021 doi: 10.1016/j.idnow.2021.07.002. - DOI - PMC - PubMed
    1. Spaccaferri G., Larrieu S., Pouey J., Calba C., Benet T., Sommen C., et al. Early assessment of the impact of mitigation measures to control COVID-19 in 22 French metropolitan areas, October to November 2020. Euro Surveill. 2020;25(50):1–5. doi: 10.2807/1560-7917.ES.2020.25.50.2001974. - DOI - PMC - PubMed
    1. Group R.C., Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., et al. Dexamethasone in hospitalized patients with COVID-19 – Preliminary report. N Engl J Med. 2020:1–11. doi: 10.1056/NEJMoa2021436. - DOI